MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP), announced today that its diabetes and obesity subsidiary, (OSI) Prosidion, has granted Bristol-Myers Squibb Company a worldwide non-exclusive license under its DPIV patent portfolio for the development and commercialization of DPIV inhibitors for the treatment of type 2 diabetes and related indications. OSI will receive an upfront payment, as well as potential future milestone and royalty payments. Additional financial terms were not disclosed.
